Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Beta Bionics is targeting a valuation of up to $695 million in an upsized initial public offering, the insulin delivery device maker said on Tuesday.

**NM signifies a non meaningful value. A dash signifies the data is not available.

**NM signifies a non meaningful value. A dash signifies the data is not available.

In trading on Tuesday, shares of Novo-Nordisk AS (Symbol: NVO) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $81 per share. By comparison ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

“Novo Nordisk retains a sizable monopoly power on ... Meanwhile, Denmark has updated its royal coat of arms to feature prominent symbols of Greenland and the Faroe Islands in solidarity with ...

The King has warned of the dangerous re-emergence of antisemitism and met with Holocaust survivors on the 80th anniversary of ...

sharewise is a website that is operated by a small team in a part-time capacity. We will try to get back to you as soon as possible, but please understand that it might take a bit of time.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs.